Competitive Edge | Insulet's tubeless patch pump technology differentiates it in diabetes care, showing strong T2II patient preferences while navigating competition from alternative treatments |
Analyst Outlook | Price targets range from $301 to $370, with an average around $326, reflecting confidence in Omnipod's technology advantages despite execution uncertainties |
Market Paradox | Despite robust Q3 earnings and overwhelming analyst support with 90% Buy ratings, the stock declined amid GLP-1 drug pricing concerns and valuation questions |
Growth Ambitions | Management unveiled a bold 20% three-year growth plan, surpassing Street estimates by 200-300 basis points through T2II market penetration and international expansion |

Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 35.4x | 8.7x | −0.5x | |
PEG Ratio | −1.56 | 0.03 | 0.00 | |
Price / Book | 8.2x | 6.2x | 2.6x | |
Price / LTM Sales | 3.7x | 3.9x | 3.1x | |
Upside (Analyst Target) | 61.1% | 44.6% | 53.0% | |
Fair Value Upside | Unlock | 9.5% | 5.9% | Unlock |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.